LFG
RAPP

Larson Financial Group’s Rapport Therapeutics RAPP Stock Holding History

Larson Financial Group’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.46K Buy
131
+29
+28% +$1.07K ﹤0.01% 2734
2026
Q1 		$3.19K Buy
102
+19
+23% +$534 ﹤0.01% 2798
2025
Q4 		$2.52K Buy
+83
New +$2.3K ﹤0.01% 2713

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Larson Financial Group's RAPP Position: Q2 2026 in Review

Larson Financial Group increased its Rapport Therapeutics (RAPP) stake by 28% in Q2 2026, buying an estimated $1.07K and bringing the position to 131 shares worth $5.46K. The position accounts for ﹤0.01% of the portfolio, ranked #2734.

Larson Financial Group first reported a position in RAPP in Q4 2025 and has held it in 3 quarters since. 160 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Larson Financial Group held 131 shares of Rapport Therapeutics worth $5.46K as of Q2 2026.
  • Larson Financial Group bought 29 Rapport Therapeutics shares in Q2 2026, an estimated $1.07K.
  • Rapport Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #2734 holding.
  • Larson Financial Group first reported a position in Rapport Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 160 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.